Novartis to Buy Anthos Therapeutics From Blackstone

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its cardiovascular pipeline.
Novartis buys Blackstone's Anthos for up to $3.1 billion
By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.
Novartis agrees to acquire Anthos for up to $3.1B
Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held,
Novartis to Buy Anthos Therapeutics for $925 Million
Novartis AG has agreed to acquire Anthos Therapeutics for $925 million as the European drug giant seeks to bolster its late-stage cardiovascular pipeline.
Novartis signs agreement to acquire Anthos for $925m upfront
Novartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront payment of $925m.
M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. Novartis will pay an
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease.
Novartis to acquire Anthos for up to US$3.1 billion
Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for up to US$3.1 billion. Read more at The Business Times.
Blackstone sells Anthos to Novartis for up to $3.1bn
Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases. It is based in Boston.
FierceBiotech2h
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
MM&M3d
Novartis’ chief marketing officer on the drugmaker’s Super Bowl ad debut
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
Super Bowl Highlights Breast Cancer Awareness In Novartis Commercial With Wanda Sykes
The Super Bowl tackled breast cancer awareness in a new Novartis Commercial featuring survivor and comedian Wanda Sykes.
FiercePharma20h
Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in the country
Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...
Novartis Wins at the 2025 Kellogg School Super Bowl Advertising Review
Novartis took home the top spot in the 21st Kellogg School Super Bowl Advertising Review with its "Your Attention, Please" ad putting a spotlight on breast health and encouraging cancer screening – ...
Bangladesh Sangsbad Sangstha19h
Writ seeking probe Novartis share transfer removed from cause list
DHAKA, Feb 10, 2025 (BSS) - The writ petition regarding the transfer of shares of Novartis Bangladesh Limited has been ...
Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Zacks.com on MSN4d
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...